Dr. Howard S. Glazer Joins Balanced Pharma

Howard Glazer

Featured in Inside Dentistry

Dr. Howard S. Glazer Joins Balanced Pharma

Leading dental educator predicts huge impact for patients, providers

Howard S. Glazer, DDS, FAGD has joined Balanced Pharma’s Scientific Advisory Board.

Dr. Glazer, an award-winning, leading voice in dental education, joins the dentist-founded pharmaceutical startup Balanced Pharma as they progress toward commercialization of BPI-001 and BPI-002, their first pipeline drugs in development.  Dr. Glazer and other key opinion leaders believe BPI-001 and BPI-002 are likely to be “game-changers” in the billion-dollar-plus injectable dental anesthetic category.

“We are honored to welcome Dr. Glazer to our Scientific Advisory Board,” says Dr. Scott Keadle, CEO of Balanced Pharma. “His exceptional abilities, experience, and well-earned trust in the dental community will help our talented team put better products into the hands of clinicians.”

Balanced Pharma intends for BPI-001 and BPI-002 to be highly differentiated, best-in-class, dental anesthetics that can deliver less painful, faster-acting, and more reliable numbing injections1., Balanced Pharma’s patented container technology will allow delivery of acid-free formulations of the existing generics (lidocaine/epinephrine and articaine/epinephrine) in a standard dental cartridge, with a standard shelf-life, for a seamless product replacement.

Dr. Glazer said, “More comfortable injections, less time in the dental chair, and more reliable anesthesia? In a standard dental cartridge, without the hassle and expense of buffering kits? Count me in.”

He continues, “The dental community has been asking for an acid-free product in a standard cartridge for decades. Now we have a way to do it, and we’re going to do it.”
About Dr. Howard S. Glazer

Dr. Glazer is a Fellow and Past President of the Academy of General Dentistry and former Assistant Clinical Professor in Dentistry at the Albert Einstein College of Medicine in New York. He has been a visiting clinician at several universities and lectures throughout the United States and internationally about dental materials, cosmetic dentistry, forensic dentistry, and patient management.

For the past several years, Dr. Glazer has been named as one of the “Leading Clinicians in Continuing Education” by Dentistry Today.  Recently, he received the prestigious New York University Smigel Prize for Distinguished Achievement in the Art and Science of Aesthetic Dentistry.

Dr. Glazer is a frequent author of dental articles and has been published throughout the world. He previously published the column “What’s Hot and What’s Getting Hotter!” in AGD Impact, the news magazine for the Academy of General Dentistry, and today publishes the column “I Have It… You Need It!” in Dental Economics.  He is a podcast contributor to Through the Loupes and maintains a general practice in Fort Lee, New Jersey, where he has been recognized as one of the top dentists in the state.

About Balanced Pharma, Inc.

Balanced Pharma, Inc. (BPI) is a pharmaceutical company based in Cornelius, North Carolina.  BPI intends to reduce injection pain, speed the onset of anesthesia, and increase the success rate of local anesthetic injections by developing and seeking regulatory approval for pH-balanced formulations of the most common local anesthetics in dental and medical procedures (lidocaine with epinephrine, articaine with epinephrine).  BPI holds patents and patents pending for dual-chamber drug-container technology that may enable new or improved drug combinations, including local anesthetics and long-acting post-surgical local analgesics.

BPI’s products are currently in development, have not been approved by the FDA, and are not available for marketing or sale.


View the full article in Inside Dentistry

1 “Effectiveness of buffered and non-buffered local anaesthetic in inferior alveolar nerve block: A randomised study”, M. Bala, A.O. Taiwo, A.A. Ibikunle, H.O. Olasoji, A.O. Sulaiman, B.C. Chukwuma, R.O. Braimah, B.O. Ile-Ogedengbe; Published in the British Journal of Oral and Maxillofacial Surgery, April 21, 2023; https://www.bjoms.com/article/S0266-4356(23)00108-0/fulltext

2 “58% of patients believe the injection is the worst part of the dental experience,” Olson Research Group, “Patient Dental Care Study Quantitative Report, Conducted for Balanced Pharma, May 7, 2021,” Fielding: March 30–April 23, 2021, total sample size: n=140 (includes 40 parents/caregivers);

 “Over 90% of dentists report a desire for current anesthetics to be more reliable, less painful, or faster acting,” Olson Research Group, “Dentist Quantitative Report, Conducted for Balanced Pharma, August 13, 2021,” Fielding: June 18–July 19, 2021, total sample size: n=181;

Please acknowledge the following to continue

I acknowledge that all Balanced Pharma Incorporated (BPI) products are currently in development and have not been evaluated or approved by FDA or any other regulatory body.

Products mentioned on this website are not available for sale, distribution, or use in any jurisdiction.